Sunovion Receives Complete Response Letter from FDA for Parkinson’s Disease Drug

Sunovion Pharmaceuticals Inc. (Sunovion) announced on 1/31/19 that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for apomorphine sublingual film (APL-130277) to treat OFF episodes (the re-emergence or worsening of Parkinson’s symptoms otherwise controlled by medications) experienced by people living with Parkinson’s disease (PD).